New drug combo shows promise for tough cancers

NCT ID NCT03363893

Completed Disease control Sponsor: Carrick Therapeutics Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called CT7001, alone or with other cancer treatments, in 124 people with advanced solid tumors like breast and prostate cancer. The main goal was to check safety and side effects. The drug is taken by mouth and aims to control the disease, not cure it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer castration-resistant prostate carcinoma hormone receptor-positive breast cancer neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID MALIGNANCIES

Contacts and locations

Locations

Research Site 1

Manchester, M20 4BX, United Kingdom
Research Site 10

Liverpool, L69 3BX, United Kingdom
Research Site 2

Oxford, OX3 7LE, United Kingdom
Research Site 3

London, W2 1NY, United Kingdom
Research Site 31

Beverly Hills, California, 90211, United States
Research Site 33

Salem, Virginia, 24153, United States
Research Site 34

Boston, Massachusetts, 02215, United States
Research Site 36

Portland, Oregon, 97239, United States
Research Site 37

Tampa, Florida, 33612, United States
Research Site 38

Chicago, Illinois, 60611, United States
Research Site 39

Columbus, Ohio, 43212, United States
Research Site 4

Manchester, M20 4BX, United Kingdom
Research Site 44

Austin, Texas, 78705, United States
Research Site 46

Dallas, Texas, 75246, United States
Research Site 47

Cincinnati, Ohio, 45236, United States
Research Site 48

Salt Lake City, Utah, 84112, United States
Research Site 54

Tucson, Arizona, 85719, United States
Research Site 6

Southampton, SO16 6YD, United Kingdom
Research Site 7

Glasgow, G12 0YN, United Kingdom
Research Site 8

London, W1G 6AD, United Kingdom
Research Site 9

London, SE1 9RT, United Kingdom
Research site 11

Brighton, BN2 5BE, United Kingdom
Research site 5

Cambridge, CB2 0QQ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.